Tc Biopharm Holdings Stock Current Asset
| TCBP Stock | USD 0.64 0.02 3.03% |
TC BioPharm Holdings fundamentals help investors to digest information that contributes to TC BioPharm's financial success or failures. It also enables traders to predict the movement of TCBP Stock. The fundamental analysis module provides a way to measure TC BioPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TC BioPharm stock.
At this time, TC BioPharm's Non Current Assets Total are relatively stable compared to the past year. As of 11/27/2024, Other Current Assets is likely to grow to about 4.3 M, while Total Current Assets are likely to drop slightly above 5.2 M. TCBP | Current Asset |
TC BioPharm Holdings Company Current Asset Analysis
TC BioPharm's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
TCBP Current Asset Historical Pattern
Today, most investors in TC BioPharm Stock are looking for potential investment opportunities by analyzing not only static indicators but also various TC BioPharm's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of TC BioPharm current asset as a starting point in their analysis.
TC BioPharm Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
TCBP Total Assets
Total Assets |
|
In accordance with the recently published financial statements, TC BioPharm Holdings has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
TCBP Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TC BioPharm's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TC BioPharm could also be used in its relative valuation, which is a method of valuing TC BioPharm by comparing valuation metrics of similar companies.TC BioPharm is currently under evaluation in current asset category among its peers.
TCBP Fundamentals
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 | ||||
| Current Valuation | 1.32 M | ||||
| Shares Outstanding | 572.02 K | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 64.93 K | ||||
| Price To Book | 0.28 X | ||||
| Price To Sales | 0.51 X | ||||
| Gross Profit | 3.84 M | ||||
| EBITDA | (13.61 M) | ||||
| Net Income | (5.91 M) | ||||
| Cash And Equivalents | 1.57 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.19 X | ||||
| Book Value Per Share | 3.38 X | ||||
| Cash Flow From Operations | (10.54 M) | ||||
| Short Ratio | 0.05 X | ||||
| Earnings Per Share | (192.95) X | ||||
| Target Price | 140.0 | ||||
| Number Of Employees | 41 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 360.37 K | ||||
| Total Asset | 8.93 M | ||||
| Retained Earnings | (38.84 M) | ||||
| Working Capital | 950.33 K | ||||
| Net Asset | 8.93 M |
About TC BioPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TC BioPharm Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with TC BioPharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.Moving together with TCBP Stock
| 0.67 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.76 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against TCBP Stock
| 0.67 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.46 | KZR | Kezar Life Sciences | PairCorr |
| 0.41 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.37 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.